Clinical Trials · NCT06305598

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Name: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 1Gonadorelin

Phase: Phase 1
Recruitment status: Active Not Recruiting
Sponsor: Roswell Park Cancer Institute
Enrollment: 3
Start date: Dec 2024
Locations: 1 site, United States
Primary endpoint: Androgen receptor (AR) activity

View Gonadorelin compound reference